| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,600,000 |
| Market
Cap: |
118.58(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.24 - $3.24 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stuart Iain |
Chief Scientific Officer |
• – – |
2019-04-01 |
4 |
S |
$3.75 |
$6,360 |
D/D |
(1,696) |
64,475 |
|
- |
|
| Harsch Mutya |
CLO and General Counsel |
• – – |
2019-04-01 |
4 |
S |
$3.75 |
$9,446 |
D/D |
(2,519) |
52,608 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2019-03-05 |
4 |
B |
$3.76 |
$50,534 |
D/D |
13,440 |
63,440 |
2.74 |
- |
|
| Harsch Mutya |
CLO and General Counsel |
• – – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,127 |
55,127 |
|
- |
|
| Domzalski David |
CEO |
• • – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
73,282 |
219,691 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,569 |
66,171 |
|
- |
|
| Hadar Ilan |
CFO & Country Manager |
• – – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,712 |
133,091 |
|
- |
|
| Domzalski David |
CEO |
• • – |
2018-12-03 |
4 |
S |
$4.05 |
$275 |
D/D |
(68) |
146,409 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2018-12-03 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Schwartz Aharon |
Director |
– • – |
2018-11-28 |
4 |
B |
$3.88 |
$47,373 |
D/D |
12,200 |
112,200 |
2.39 |
- |
|
| Schwartz Aharon |
Director |
– • – |
2018-11-27 |
4 |
B |
$3.92 |
$195,800 |
D/D |
50,000 |
100,000 |
2.39 |
- |
|
| Schwartz Aharon |
Director |
– • – |
2018-11-26 |
4 |
B |
$3.89 |
$194,600 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
| Howard Alvin D |
VP Regulatory |
• – – |
2018-11-19 |
4 |
S |
$3.90 |
$13,163 |
D/D |
(3,375) |
38,414 |
|
- |
|
| Domzalski David |
CEO |
• • – |
2018-11-19 |
4 |
S |
$3.90 |
$19,640 |
D/D |
(5,036) |
146,477 |
|
- |
|
| Stuart Iain |
SVP R&D |
• – – |
2018-11-08 |
4 |
S |
$4.58 |
$3,128 |
D/D |
(683) |
33,602 |
|
- |
|
| Domzalski David |
CEO |
• • – |
2018-11-08 |
4 |
S |
$4.58 |
$9,444 |
D/D |
(2,062) |
151,513 |
|
- |
|
| Howard Alvin D |
VP Regulatory |
• – – |
2018-10-01 |
4 |
S |
$5.81 |
$1,360 |
D/D |
(234) |
41,789 |
|
- |
|
| Elliott Russell P. |
VP Drug Development |
• – – |
2018-10-01 |
4 |
S |
$5.81 |
$825 |
D/D |
(142) |
12,442 |
|
- |
|
| Domzalski David |
CEO |
• • – |
2018-10-01 |
4 |
S |
$5.81 |
$3,492 |
D/D |
(601) |
153,575 |
|
- |
|
| Domzalski David |
CEO |
• • – |
2018-09-04 |
4 |
S |
$5.67 |
$380 |
D/D |
(67) |
154,176 |
|
- |
|
| Domzalski David |
CEO |
• • – |
2018-08-08 |
4 |
S |
$5.68 |
$46,792 |
D/D |
(8,238) |
154,243 |
|
- |
|
| Stuart Iain |
SVP R&D |
• – – |
2018-08-08 |
4 |
S |
$5.68 |
$15,421 |
D/D |
(2,715) |
34,285 |
|
- |
|
| Hirsch Stanley |
Director |
– • – |
2018-07-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,616 |
12,974 |
|
- |
|
| Domzalski David |
CEO |
• • – |
2018-07-02 |
4 |
S |
$5.10 |
$3,070 |
D/D |
(602) |
162,481 |
|
- |
|
| Elliott Russell P. |
VP Drug Development |
• – – |
2018-07-02 |
4 |
S |
$5.10 |
$724 |
D/D |
(142) |
12,584 |
|
- |
|
111 Records found
|
|
Page 3 of 5 |
|
|
